SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)

SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC30A5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 30 Member 5 (SLC30A5)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3p21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7783](https://www.ncbi.nlm.nih.gov/gene/7783)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607339](https://www.omim.org/entry/607339)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146039</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q8TAP9](https://www.uniprot.org/uniprot/Q8TAP9)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Zinc transporter 5 (ZnT5)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Potential role in zinc homeostasis, neurodegeneration</td>
</tr>
<tr>
<td class="label">Zinc Pool</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Cytosolic free zinc</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td class="label">Golgi zinc</td>
<td>Golgi lumen</td>
</tr>
<tr>
<td class="label">Vesicular zinc</td>
<td>Secretory vesicles</td>
</tr>
<tr>
<td class="label">Stored zinc</td>
<td>Lysosomes, vesicles</td>
</tr>
<tr>
<td class="label">Transporter</td>

SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC30A5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 30 Member 5 (SLC30A5)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3p21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7783](https://www.ncbi.nlm.nih.gov/gene/7783)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607339](https://www.omim.org/entry/607339)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146039</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q8TAP9](https://www.uniprot.org/uniprot/Q8TAP9)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Zinc transporter 5 (ZnT5)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Potential role in zinc homeostasis, neurodegeneration</td>
</tr>
<tr>
<td class="label">Zinc Pool</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Cytosolic free zinc</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td class="label">Golgi zinc</td>
<td>Golgi lumen</td>
</tr>
<tr>
<td class="label">Vesicular zinc</td>
<td>Secretory vesicles</td>
</tr>
<tr>
<td class="label">Stored zinc</td>
<td>Lysosomes, vesicles</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Function</td>
</tr>
<tr>
<td class="label">ZIP1</td>
<td>Zinc uptake</td>
</tr>
<tr>
<td class="label">ZIP14</td>
<td>Neuronal uptake</td>
</tr>
<tr>
<td class="label">ZnT1</td>
<td>Zinc efflux</td>
</tr>
<tr>
<td class="label">ZnT6</td>
<td>Golgi transport</td>
</tr>
<tr>
<td class="label">ZnT10</td>
<td>Lysosomal export</td>
</tr>
</table>

{{.infobox .infobox-gene}}

Overview

SLC30A5 (Zinc Transporter 5, ZnT5) is a member of the SLC30 family of zinc transporters that facilitates zinc efflux from the cytoplasm into intracellular compartments[@huang2013]. ZnT5 is primarily localized to the Golgi apparatus and plasma membrane, where it plays a critical role in zinc sequestration and homeostasis[@nishida2009]. The gene is expressed in various tissues including the brain, making it relevant to neurodegenerative disease research[@jackson2007].

The SLC30 (ZnT) family consists of ten members (ZnT1-10) that mediate cellular zinc efflux or sequestration into intracellular organelles. ZnT5 (SLC30A5) is one of the larger members of this family, with predicted topology featuring six transmembrane domains and an extended N-terminal region. Unlike some other ZnT members, ZnT5 operates as a proton/zinc antiporter, using the proton gradient to drive zinc transport against its concentration gradient.

Zinc is an essential trace metal required for numerous biological processes, including enzyme catalysis, protein structure stabilization, and signaling. In the brain, zinc plays particularly important roles in synaptic transmission, synaptic plasticity, and neuronal survival. However, both zinc deficiency and zinc excess can be pathological, highlighting the importance of precise zinc homeostasis maintained by zinc transporter families including ZIP (SLC39A) and ZnT (SLC30A).

Gene Structure and Expression

Genomic Organization

The SLC30A5 gene (Ensembl: ENSG00000146039) is located on chromosome 3p21.1, a region that has been linked to various neurological conditions. The gene spans approximately 35 kb and contains 13 exons that encode a protein of 638 amino acids. Alternative splicing generates multiple transcript variants with distinct tissue distributions.

Tissue Distribution

ZnT5 shows broad tissue expression with particularly high levels in[@chintapalli2020]:

• Brain (cerebral cortex, hippocampus, cerebellum)
• Testis
• Intestine
• Heart
• Lung

Transcriptional Regulation

SLC30A5 expression is regulated at multiple levels[@jackson2007]:

Protein Structure and Function

Transmembrane Topology

ZnT5 belongs to the CDF (cation diffusion facilitator) family of metal transporters. The predicted structure includes[@watowich2020]:

• Six transmembrane helices: Forming the core transport channel
• N-terminal regulatory domain: Contains potential regulatory phosphorylation sites
• C-terminal tail: Intracellular location with potential regulatory functions
• Histidine-rich loop: Between transmembrane helices IV and V, involved in zinc binding

Transport Mechanism

ZnT5 operates as a Zn²⁺/H⁺ antiporter[@kambe2020]:

This proton-coupled mechanism allows ZnT5 to concentrate zinc in acidic compartments like the Golgi, where the luminal pH is lower than the cytoplasm.

Role in Zinc Homeostasis

Cellular Zinc Pools

ZnT5 contributes to multiple cellular zinc pools[@sensel2021]:

Interplay with Other Transporters

Zinc homeostasis requires coordinated action of multiple transporters:

• ZIP transporters: Bring zinc into the cytoplasm from extracellular space and intracellular organelles
• ZnT transporters: Mediate zinc efflux to organelles and extracellular space
• Metallothioneins: Buffer cytosolic zinc levels

Zinc in Neurodegeneration

Alzheimer's Disease

Zinc dyshomeostasis is a prominent feature of AD pathophysiology[@hara2021][@ayton2022]:

Amyloid-β and Zinc

Zinc interacts with Aβ in several critical ways:

• Zinc promotes Aβ aggregation: In vitro studies show zinc accelerates Aβ fibril formation
• Aβ-Zn complexes: Form distinct pathological species with enhanced toxicity
• Zinc alters APP processing: Zinc levels influence secretase activity

Tau Pathology

Zinc homeostasis is linked to tau pathology:

• Zinc-dependent kinases/phosphatases regulate tau phosphorylation
• Zinc chelation can modulate tau phosphorylation status
• Zinc dysregulation contributes to neurofibrillary tangle formation

Synaptic Zinc Dysregulation

In AD, synaptic zinc handling is impaired:

• Abnormal zinc accumulation in neurons
• Disrupted activity-dependent zinc release
• Impaired synaptic plasticity

Parkinson's Disease

Zinc also plays important roles in PD pathogenesis[@kim2019][@potts2021]:

Dopaminergic Neuron Vulnerability

Zinc dysregulation contributes to dopaminergic neuron vulnerability:

• Zinc can potentiate oxidative stress
• Altered zinc homeostasis affects mitochondrial function
• Zinc promotes alpha-synuclein aggregation

Neuroinflammation

Zinc and neuroinflammation are interconnected:

• Activated microglia show altered zinc transporter expression
• Zinc modulates cytokine production
• Anti-inflammatory therapies may work partially through zinc pathways

Other Neurodegenerative Conditions

Zinc transporters are implicated in other conditions[@lee2022]:

• Amyotrophic lateral sclerosis: ZnT expression altered in motor neurons
• Huntington's disease: Zinc dysregulation in affected brain regions
• Multiple sclerosis: ZnT variants associated with disease risk

Therapeutic Implications

Zinc-Based Therapies

Targeting zinc homeostasis offers therapeutic potential[@levy2024]:

Zinc Chelation

Strategic approaches include:

• Moderate zinc chelation to reduce pathological zinc accumulation
• Temporal targeting during specific disease phases
• Blood-brain barrier penetrating chelators

Zinc Supplementation

In some cases, zinc therapy may be beneficial:

• Correcting deficiency-associated neurodegeneration
• Supporting synaptic function
• Enhancing metallothionein expression

Targeting ZnT5

Specific strategies include[@fogelman2023]:

• Upregulating ZnT5 expression: Enhance zinc sequestration
• Pharmacological activation: Increase transporter activity
• Gene therapy: Deliver functional ZnT5 variants

Other Zinc Transporters in Brain

Neurodevelopment and ZnT5

Brain Development

ZnT5 plays roles in neurodevelopment[@goswert2022]:

• Neuronal differentiation: Zinc signaling during fate specification
• Synaptogenesis: Zinc accumulation in presynaptic vesicles
• Myelination: Oligodendrocyte zinc homeostasis

Critical Periods

Zinc homeostasis is particularly important during:

• Prenatal brain development
• Early postnatal synaptogenesis
• Adolescent synaptic pruning

Genetics and Disease Risk

Variants and Polymorphisms

Genetic variants in SLC30A5 have been associated with:

• Neurological conditions: Developmental disorders, cognitive impairment
• Systemic diseases: Diabetes, immune disorders
• Population variants: Common polymorphisms may affect disease risk

Gene-Environment Interactions

SLC30A5 variants may interact with:

• Dietary zinc: Absorption and utilization
• Environmental toxins: Heavy metal exposure
• Aging: Age-related expression changes

Biomarkers and Diagnostics

Measuring Zinc Homeostasis

Clinical assessment includes[@barnes2020]:

• Serum zinc: Easily measurable but limited brain correlation
• CSF zinc: More relevant to CNS status
• Genomic markers: SLC30A5 variants as risk indicators

Imaging Modalities

Advanced approaches include:

• Zinc-sensitive MRI: Emerging neuroimaging techniques
• PET tracers: Molecular imaging of zinc pools

Summary

SLC30A5 (ZnT5) is a zinc transporter that sequesters zinc into intracellular compartments, particularly the Golgi apparatus. In the brain, ZnT5 contributes to synaptic zinc handling, secretory pathway function, and overall zinc homeostasis. Dysregulation of ZnT5 and other zinc transporters contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Zinc homeostasis represents a promising therapeutic target, with strategies including zinc chelation, supplementation, and transporter modulation under active investigation.

Evolutionary Perspectives

Phylogenetic Conservation

The ZnT family shows interesting evolutionary patterns:

• SLC30A5 orthologs: Present in vertebrates and some invertebrates
• Conservation of transport mechanism: Proton-zinc antiporter mechanism conserved
• Brain expression: Emerging in complex nervous systems

Species-Specific Features

Different species show adaptations:

• Vertebrate complexity: Multiple isoforms and splice variants
• Dysregulation patterns: Species-specific disease vulnerabilities
• Therapeutic targeting: Cross-species applicability

Methodological Approaches

Studying ZnT5 Function

Key experimental approaches include:

Challenges and Limitations

Current approaches face several challenges:

• Brain-specific function: Difficulty modeling CNS zinc dynamics
• Temporal resolution: Need for real-time zinc imaging
• Compartmental complexity: Multiple zinc pools in neurons

Clinical Translation

Diagnostic Development

ZnT5 as a biomarker target:

• Genetic screening: SLC30A5 variants in patient populations
• Expression analysis: Brain tissue and CSF measurements
• Functional assays: Lymphocyte zinc transport function

Therapeutic Development

Drug discovery approaches include:

• High-throughput screening: Identifying ZnT5 modulators
• Structure-based design: Computer-aided drug design
• In vivo testing: Animal model efficacy

Patient Stratification

Precision medicine approaches:

• Genotyping: SLC30A5 variant identification
• Zinc status: Baseline measurement before therapy
• Response prediction: Pharmacogenomics of zinc-based therapies

Network Biology

Protein-Protein Interactions

ZnT5 interacts with multiple proteins:

• ZIP transporters: Complementary zinc transport
• Metallothioneins: Zinc buffering
• Secretory pathway proteins: Golgi function
• Signaling proteins: Kinase and phosphatase interactions

Systems-Level Understanding

Integrative approaches model:

• Zinc network: Global cellular zinc handling
• Disease networks: Perturbed in neurodegeneration
• Therapeutic networks: Targets and offtargets

Future Research Directions

Unanswered Questions

Key questions remain:

Emerging Areas

New research directions include:

• Single-cell analysis: ZnT5 expression in specific cell types
• Temporal dynamics: Changes during disease progression
• Spatial mapping: Regional brain vulnerabilities

Technology Development

Advances needed include:

• Better zinc sensors for in vivo imaging
• Cell-type specific knockouts
• Human brain organoid models

Conclusion

SLC30A5 represents a critical node in cellular zinc homeostasis with particular importance in the central nervous system. As a proton-coupled zinc antiporter localized primarily to the Golgi apparatus, ZnT5 sequesters zinc into the secretory pathway, contributing to protein processing, synaptic zinc handling, and overall cellular zinc balance. The growing evidence linking zinc transporter dysfunction to neurodegenerative diseases positions SLC30A5 as both a contributor to disease pathogenesis and a potential therapeutic target.

The complex interplay between zinc homeostasis and neurodegeneration suggests that precise modulation—rather than blanket supplementation or chelation—may provide the most therapeutic benefit. Understanding the specific roles of individual zinc transporters, including SLC30A5, in disease-specific contexts will be essential for developing effective neuroprotective strategies targeting this emerging molecular mechanism of disease, providing hope for patients with zinc dysregulation-associated neurodegeneration in coming years.

Function

ZnT5 functions as a zinc/proton antiporter, transporting zinc ions from the cytoplasm into the Golgi lumen and other intracellular compartments[@huang2013]. This activity is crucial for:

• Zinc sequestration: Regulating cellular zinc levels by sequestering excess zinc into intracellular stores
• Enzymatic cofactor delivery: Providing zinc as a cofactor for zinc-dependent enzymes in the Golgi
• Secretory pathway function: Supporting proper folding and processing of zinc-dependent proteins

Role in Neurodegeneration

Zinc homeostasis is critically disrupted in Alzheimer's disease (AD) and Parkinson's disease (PD)[@nuttall2009]. Dysregulation of zinc transporters, including ZnT5, may contribute to:

Expression Patterns

SLC30A5 is widely expressed across human tissues with high expression in the brain, particularly in [neurons](/entities/neurons) and glial cells[@jackson2007]. Studies have shown age-related decline in SLC30A5 expression, which may contribute to the ageing-related decline in zinc status[@nuttall2009].

Clinical Significance

Recent studies have identified SLC30A5 variants in patients with severe neonatal hypotonia, demonstrating the critical role of ZnT5 in neurological function[@elbacha2024]. Additionally, promoter methylation of SLC30A5 may contribute to age-related decline in zinc status[@nuttall2009].

Key Publications

See Also

• [Zinc Homeostasis](/mechanisms/zinc-homeostasis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [SLC30 Family](/entities/slc30-family)

References